Download PDF
Dtsch Med Wochenschr 2004; 129(34/35): 1821-1826
DOI: 10.1055/s-2004-831344
Übersichten
Gastroenterologie/Infektiologie
© Georg Thieme Verlag Stuttgart · New York

Helicobacter-pylori Infektion - ein Update 2004

Helicobacter pylori infection - update for the clinician 2004P. Malfertheiner1 , U. Peitz1 , K. Wolle1 , G. Treiber1
  • 1Klinik für Gastroenterologie, Hepatologie und Infektiologie der Otto-von-Guericke-Universität Magdeburg
Further Information

Publication History

eingereicht: 6.5.2004

akzeptiert: 9.8.2004

Publication Date:
16 August 2004 (online)

Also available at
   Permissions and Reprints

Auch im Jahr 2004 bleibt die Beschäftigung mit der Helicobacter-pylori(H.p.)-Infektion eine spannende Herausforderung für Klinik und Grundlagenforschung [46]. Die H.p.-Therapie zur Heilung der peptischen Ulkuskrankheit ist zwar allgemein akzeptiert, allerdings lässt die letzte Konsequenz der Umsetzung dieser Behandlung in der Praxis immer noch Wünsche offen. Die klinische Diskussion dreht sich weiterhin um Indikationsstellungen zur Behandlung der H.p.-Infektion, wenn noch keine Komplikationen eingetreten sind. Aktuell sind vor allem Fragen, ob Patienten mit dyspeptischen Beschwerden bei H.p.-positiver Gastritis von dieser Therapie profitieren, ob die Behandlung der Infektion vor Schäden durch nicht-steroidale Antirheumatika (NSAR) schützt, und nicht zuletzt, ob eine Prävention des Magenkarzinoms durch H.p.-Eradikation erreicht werden kann.

Literatur

  • 1 Birkner B, Hotz J, Labenz J. et al . Kurzgefasste Leitlinie zum Dyspepsie-Management.  Dtsch Med Wochenschr. 2004;  129 (18) 1032-1034
    Google Scholar
  • 2 Blaser M J. Hypothesis: the changing relationship of H.p. and humans: implications for health and disease.  J Infect Dis. 1999;  179 1523-1530
    Google Scholar
  • 3 Brenner H, Arndt V, Stegmaier C. et al . Is H.p. infection a necessary condition for noncardia gastric cancer?.  Am J Epidemiol. 2004;  159 252-258
    Google Scholar
  • 4 Chan F K, Chung S C, Suen B Y. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.  N Engl J Med. 2001;  344 967-973
    Google Scholar
  • 5 Chan F K, To K F, Wu J C. et al . Eradication of H.p. and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.  Lancet. 2002;  359 9-13
    Google Scholar
  • 6 Chiba N, Veldhuyzen Van Zanten S JO, Escobedo S. et al . Economic evaluation of H.p. eradication in the CADET-Hp randomized controlled trial of H.p. positive primary care patients with uninvestigated dyspepsia.  Aliment Pharmacol Ther. 2004;  19 349-358
    Google Scholar
  • 7 Chiba N, Veldhuyzen Van Zanten S JO, Sinclair P. et al . Treating H.p. infection in primary care patients with uninvestigated dyspepsis: the Canadian adult dyspepsia empiric treatment - H.p. positive (CADET-Hp) randomised controlled trial.  Brit Med J. 2002;  324 1-7
    Google Scholar
  • 8 Churin Y, Al-Ghoul L, Kepp O. et al . Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response.  J Cell Biol. 2003;  28 (161) 249-255
    Google Scholar
  • 9 Dore M P, Osato M S, Malaty H M. et al . Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients.  Helicobacter. 2000;  5 165-168
    Google Scholar
  • 10 El Omar E M, Rabkin C S, Gammon M D. et al . Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.  Gastroenterology. 2003;  124 1193-201
    Google Scholar
  • 11 Fischbach W, Goebeler-Kolve M E, Dragosics B. et al . Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.  Gut. 2004;  53 34-37
    Google Scholar
  • 12 Gisbert J, Calvet X, Bujanda L. et al . ’Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures.  Helicobacter. 2003;  8 90-94
    Google Scholar
  • 13 Glupczynski Y, Megraud F, Lopez-Brea M. et al . European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.  Eur J Clin Microbiol Infect Dis. 2001;  20 820-823
    Google Scholar
  • 14 Glynn M K, Friedman C R, Gold B D. et al . Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors.  Clin Infect Dis. 2002;  35 1059-1065
    Google Scholar
  • 15 Granquist A, Bredberg A, Sveger T. et al . A longitudinal cohort study on the prevalence of Helicobacter pylori antibodies in Swedish children and adolescents.  Acta Paediatr. 2002;  91 636-640
    Google Scholar
  • 16 Grimm W, Fischbach W. Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms.  Dtsch Med Wochenschr. 2003;  128 1878-1883
    Google Scholar
  • 17 Heuberger F, Pantoflickowa D, Gassner M. et al . H.p. infection in Swiss adolescents. Prevalence and risk factors.  Eur J Gastroenterol Hepatol. 2003;  15 179-183
    Google Scholar
  • 18 Huang J, Hunt R. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole.  Aliment Pharmacol Ther. 1999;  13 857-64
    Google Scholar
  • 19 Kist M, Glocker E. Helicobacter pylori Infektionen: ResiNet - eine bundesweite Sentinelstudie zur Resistenzentwicklung.  Epidemiol Bull. 2003;  47 389-391
    Google Scholar
  • 20 Klotz U, Schwab M, Treiber G. CYP2C19 Polymorphism and Proton Pump Inhibitors.  Basic Clin Pharmacol Toxicol. 2004;  95 2-8
    Google Scholar
  • 21 Kuipers E J, Nelis G F, Klinkenberg-Knol E C. et al . Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.  Gut. 2004;  53 12-20
    Google Scholar
  • 22 Labenz J, Blum A L, Bolten W W. et al . Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in H.p. positive patients: a randomised, double blind, placebo controlled, clinical trial.  Gut. 2002;  51 329-335
    Google Scholar
  • 23 Lai K C, Lam S K, Chu K M. et al . Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.  N Engl J Med. 2002;  346 2033-2038
    Google Scholar
  • 24 Leodolter A, Dominguez-Munoz J E, Von Arnim U. et al . Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting.  Am J Gastroenterol. 1999;  94 2100-2104
    Google Scholar
  • 25 Leodolter A, Malfertheiner P. Aktuelle diagnostische Methoden zum Nachweis der Helicobacter-pylori-Infektion.  Dtsch Med Wochenschr. 2001;  126 207-209
    Google Scholar
  • 26 Leodolter A, Wolle K, Malfertheiner P. Current standards in the diagnosis of H. pylori infection.  Dig Dis. 2001;  19 116-122
    Google Scholar
  • 27 Leodolter A, Peitz U, Ebert M P. et al . Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy.  Am J Gastroenterol. 2002;  97 1682-1686
    Google Scholar
  • 28 Leodolter A, Vaira D, Bazzoli F. et al . European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test.  Aliment Pharmacol Ther. 2003;  18 927-931
    Google Scholar
  • 29 Leodolter A, Wolle K, Peitz U. et al . Evaluation of a near-patient fecal antigen test for the assessment of Helicobacter pylori status.  Diagn Microbiol Infect Dis. 2004;  48 145-147
    Google Scholar
  • 30 Malfertheiner P. H.p. eradication does not exacerbate gastro-oesophageal reflux disease.  Gut. 2004;  53 312-313
    Google Scholar
  • 31 Malfertheiner P, Megraud F, O’Morain C. et al . Current concepts in the management of Helicobacter pylori infection - The Maastricht 2 - 2000 Consensus Report.  Aliment Pharmacol Ther. 2002;  16 167-180
    Google Scholar
  • 32 Malfertheiner P, Mössner J, Fischbach W. et al . H.p. eradication is beneficial in the treatment of functional dyspepsia.  Aliment Pharmacol Ther. 2003;  15 615-625
    Google Scholar
  • 33 Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy?.  Can J Gastroenterol. 2003;  17 (Suppl B) 53B-57B
    Google Scholar
  • 34 Manes G, Menchise A, De Nucci C. et al . Empirical prescribing for dyspepsia. randomised controlled trial of test and treat versus omeprazole treatment.  Brit Med J. 2003;  326 1118
    Google Scholar
  • 35 Mc Coll K EL, Murray L S, Gillen D. et al . Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H.p. testing alone in the management for dyspepsia.  Brit Med J. 2002;  324 999-1002
    Google Scholar
  • 36 Meining A G, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients.  Eur J Gastroenterol Hepatol. 1999;  11 717-720
    Google Scholar
  • 37 Melo E T, Lopes E P, Almeida J R, Albuquerque  H F, Moura I M. Seroprevalence of H. pylori antibodies in medical students and residents in Recife, Brazil.  Clin Gastroenterol. 2003;  36 134-8
    Google Scholar
  • 38 Mitchell H M, Hu P, Chi Y. et al . A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation.  Gastroenterology. 1998;  114 256-261
    Google Scholar
  • 39 Nardone G, Morgner A. Helicobacter pylori and gastric malignancies.  Helicobacter. 2003;  8,1 44-52
    Google Scholar
  • 40 Osato M S, Reddy R, Graham D Y. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States.  Int J Antimicrob Agents. 1999;  12 341-347
    Google Scholar
  • 41 Peitz U, Leodolter A, Wex T. et al . Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding.  Z Gastroenterol. 2004;  42 141-146
    Google Scholar
  • 42 Raymond J, Kalach N, Bergeret M. et al . Prevalence of Helicobacter pylori infection in children according to their age. A retrospective study.  Arch Pediatr. 1998;  5 617-620
    Google Scholar
  • 43 Roma-Giannikou E, Karameris A, Balatsos B. et al . Intrafamilial spread of Helicobacter pylori: a genetic analysis.  Helicobacter. 2003;  8 15-20
    Google Scholar
  • 44 Rothenbacher D, Brenner H. Burden of H.p. and H.p.-related diseases in developed countries: recent developments and future implications.  Microbes Infect. 2003;  5 (8) 693-703
    Google Scholar
  • 45 Schilling D, Demel A, Adamek H E. et al . A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study.  Dig Liver Dis. 2003;  35 217-221
    Google Scholar
  • 46 Suerbaum S, Michetti P. Helicobacter pylori infection.  N Engl J Med. 2002;  347 1175-86
    Google Scholar
  • 47 Triantafillidis J K, Gikas A, Hyphantis T. et al . Helicobacter pylori infection in hospital workers over a 5-year period. Correlation with demographic and clinical parameters.  J Gastroenterol. 2002;  37 1005-1013
    Google Scholar
  • 48 Uemura N, Okamoto S, Yamamoto S. et al . H.p. infection and the development of gastric cancer.  N Engl J Med. 2001;  345 784-789
    Google Scholar
  • 49 Wolle K, Leodolter A, Malfertheiner P. et al . Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000.  J Med Microbiol. 2002;  51 705-9
    Google Scholar
  • 50 Wong B CY, Lam S K, Wong W M. et al . H.p. eradication to prevent gastric cancer in a high-risk region of China.  J Amer Med Assoc. 2004;  291 (2) 187-194
    Google Scholar

Prof. Dr. P. Malfertheiner

Klinik für Gastroenterologie, Hepatologie und Infektiologie der Otto-von-Guericke-Universität Magdeburg

Leipziger Str. 44

39120 Magdeburg

Phone: 03 91-6 71 31 00

Fax: 03 91-6 71 31 05

Email: peter.malfertheiner@medizin.uni-magdeburg.de